Over 1.8 million nonprofits and charities for donors, volunteers and funders

Claim This Nonprofit

More Info

Add to Favorites

Share this Nonprofit

Donate

Volunteering Oportunities

Nonprofit Overview

Causes: Government & Public Administration, Health, Medical Research, Mental Health, Mental Health Treatment

Mission: Founded in 1986, the Multidisciplinary Association for Psychedelic Studies (MAPS) is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS furthers its mission by: -Developing psychedelics and marijuana into prescription medicines -Training therapists and working to establish a network of treatment centers -Supporting scientific research into spirituality, creativity, and neuroscience -Educating the public honestly about the risks and benefits of psychedelics and marijuana MAPS envisions a world where psychedelics and marijuana are safely and legally available for beneficial uses, and where research is governed by rigorous scientific evaluation of their risks and benefits.

Results: MAPS has completed two Phase 2 FDA studies using MDMA-assisted psychotherapy to treat PTSD, and is in the process of four other similar studies. MAPS also has a study looking at LSD-assisted psychotherapy for treating end-of-life anxiety, an outcome study of the benefits of ibogaine for opiate dependence, and a protocol to investigate medical marijuana to relieve symptoms of PTSD.

Target demographics: Any person whose life may be aided by the transformative nature of psychedelic psychotherapy

Geographic areas served: Worldwide

Programs: Maps' primary focus is research into mdma-assisted psychotherapy ($1,094,575), especially phase 2 research into mdma-assisted psychotherapy in subjects with chronic, treatment-resistant ptsd. In this fiscal year, maps treated the 18th subject in our charleston, south carolina mdma/ptsd study in 24 veterans, firefighters and police officers. An 8th subject was treated in our study in boulder, colorado for people suffering from ptsd from any source, a fourth subject was treated in our mdma/ptsd study in beer yaakov, israel, and an irb approved the amendments for our mdma/ptsd study in vancouver, canada. A 7th therapist participated in our mdma-assisted psychotherapy therapist training study. In addition to our core clinical research, this fiscal year we began planning a series of studies in collaboration with researchers who work with the u. S. Department of veterans affairs' national center for ptsd. We'll be exploring the use of mdma along with more traditional psychotherapeutic methods for treating ptsd including cognitive-behavioral conjoint therapy, cognitive processing therapy, and prolonged exposure therapy. We also began our study looking at the safety and efficacy of using mdma-assisted therapy for anxiety in adults on the autism spectrum and began preparations for a study of mdma-assisted psychotherapy for end-of-life anxiety. These studies will grow significantly in the coming year. Mdma-study related program expenses include costs of video data storage and streaming systems development, budgeting, contracting, and meetings; the costs of developing the treatment manual; training therapists; blinded therapist adherence training; and costs of reviewing and documenting all published mdma literature. There are also mdma-study related supervision of therapists, presentation of our data at professional conferences, and costs to manage the mdma purchased early in our work and to secure the drug for phase 3 trials expected to begin in 2016. Clinical research general costs cover the development of the infrastructure needed for our mdma clinical trials, including work with communications and fundraising departments, staff professional development and conferences, and video streaming and statistical software. Most of the clinical research expenses are personnel, including personnel at each study site: principal investigators, co-investigators, independent raters, overnight physicians, attendant, and study coordinators, as well as maps' internal staff: the clinical director, research associates, information specials, data coordinators and statistical consultants. Ibogaine research expenses were dedicated to completing our studies in mexico ($3,816), and new zealand ($6,329). Lsd research expenses ($12,185) were primarily used for the march 2014 publication of our lsd end-of-life anxiety article in the journal of nervous and mental disease. Marijuana research ($14,905) covered the costs of developing the protocol for a pilot study in which marijuana will be tested to manage symptoms in 76 veterans with chronic, treatment-resistant ptsd, and our efforts to end the public health service (phs) review and the national institute of drug abuse (nida) monopoly of the sale of marijuana for clinical research.

education expenses include harm reduction, events, publications and communications programs. Our zendo project provides a supportive space for people undergoing difficult psychedelic experiences in order to help turn those experiences into opportunities for learning and personal growth, and to reduce the number of drug-related psychiatric hospitalizations and arrests. Services were provided at five major events in fiscal year 2014: burning man (black rock city, nv), envision (costa rica), afrikaburn (south africa), bicycle day (san francisco, ca), and lightning in a bottle (bradley, ca). In order to share recent findings and to inspire existing and new support, maps produced events on psychedelic and marijuana research in colorado, vancouver and santa cruz; and attended more than 17 events that others produced, providing speakers, exhibits, sales of books and maps bulletins, and free distribution of clinical protocols and articles from peer-reviewed journals. Communications included publishing three maps bulletins, and 12 email newsletters, maintaining maps. Org, mdmaptsd. Org, mapscanada. Org, psychedelicscience. Org, and launching mdma-autism. Org. Maps produced "manifesting minds," with north atlantic books, reprinted albert hofmann's "lsd: my problem child," and began work with stanislav grof on his new book, "the visionary world of h. R. Giger. " in spring 2014, maps offered its first webinar, "psychedelic science," in collaboration with evolver learning labs. Maps saw significant growth in coverage of its work in social, online, and traditional media. Maps. Org had 511,449 unique visits and 1,809,246 page views. Facebook likes more than doubled to 89,282. Twitter followers increased 140%, to 17,099. Youtube subscriptions increased 256% to 5,313. Maps received 344 unique media mentions from online and print publications with significant reach. Media outlets include the los angeles times, the new york times, the san francisco chronicle, reason, scientific american, cnn, usa today, msnbc, time, associated press, fox news, forbes, nbc news, playboy, santa cruz sentinel, tricycle, business insider, npr, vice, and southern california public radio (kpcc).

this year, maps operationalized its long-running fiscal sponsorship program, clarifying and updating contracts, process, and structure. This program supports projects that are in alignment with maps mission and vision by offering donors a way to give to a 501(c) 3 nonprofit organization. Maps monitors the project budget, takes a small fee, and sends the donor a receipt for their contribution.

Community Stories

170 Stories from Volunteers, Donors & Supporters

1 Ellen87

Donor

Rating: 5

I feel this is one of the most important groups around and I wholly support them. Psychedelic substances have made a huge contribution to my life and well being, as well as to the lives of many people I know. I think all humans have the desire to change, grow and expand their consciousness and that governments should not limit their ability to do so. MAPS has been tireless in their quest to prove the efficacy of this medicine.

3

Donor

Rating: 5

MAPS advocates using rigorous scientific studies in vetting the therapeutic potential of psychedelics. I have experienced great personal growth through the therapeutic use of psychedelics. MAPS work guarantees in the future others can share these same experiences in legal clinical settings.

Carl21

Donor

Rating: 5

Psychedelics are the cure for the human condition and MAPS is there to support in helping the human being to remember its inner and inter-connectivity to what is.

1

Donor

Rating: 5

Mr Doblin, and Dr & Mrs Mithoefer, likely would decline the designation "heroes." Nevertheless, the healing which is on the cusp of realization and for which the world owes MAPS, will show that they deserve the title. This is equally true for MAPS' other researchers and staff, though they are less in the spotlight. Money donated to MAPS goes toward the work, and I'm proud and pleased to support them.

1

Donor

Rating: 5

By developing medicines to heal trauma, addiction, depression while supporting freedom of consciousness makes MAPS the one of the most important and undervalued organisation today. Not only individuals need a non-stigmatised and non-criminalised climate to find healing, we as a species, if we want to address our own shortcomings and ailments, need it too. Therefore I support MAPS with all my love and compassion.

1 Shane9

Donor

Rating: 5

Their work is courageous and crucial.
The medicines are currently banned for emotional and political reasons.

Let's use science to decide on the potential uses.

Donor

Rating: 5

Psychedelics are the only medicines that treat my schizoaffective disorder without side effects. MAPS has worked consistently to build the scientific and evidential framework to legalize this treatment. I'm proud to support MAPS.

Donor

Rating: 5

I love MAPS for all of the work they put into cutting edge research, education, and great events! Their work is truly important for so many reasons.

Donor

Rating: 5

Groundbreaking research - long time coming - sorely needed - God bless MAPS

Review from Guidestar

Donor

Rating: 5

MAPS keep surprising year after year, steadily advancing knowledge in one of neurocscience's most promising frontiers. Simply awesome. Support their work now!

Previous Stories
10

Professional with expertise in this field

Rating: 5

MAPS is way beyond regular non-profits It's work is on the frontier of medical and neuroscientific research, and I firmly believe they're gonna be responsible for great and important positive changes in the near future, creating new therapeutic tools and helping in changing the current paradigms!

Review from Guidestar